May 29, 2020
AstraZeneca with promising results from clinics for Imfinzi and Enhertu
AstraZeneca on Friday reported several clinical results from its studies, including Imfinzi and Enhertu, with meaningful outcomes.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: durvalumab
February 20, 2019
ADC Therapeutics doses patients in testing ADCT-402, after encouraging safety profile and anti-tumor activity
Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
January 17, 2017
AstraZeneca tests overall and progression-free survivals in cancer related trials, focused on China
AstraZeneca has provided updates on some of its cancer related clinical trials including 1st-line non-small cell lung cancer (NSCLC). and a…
December 13, 2016
FDA grants priority review status for AstraZeneca’s bladder cancer drug durvalumab
AstraZeneca’s application (BLA) for durvalumab for BLA in bladder cancer was accepted by the FDA. The PD-L1 human monoclonal antibody…
October 28, 2016
AstraZeneca pauses two cancer drug trials’ enrolment due to bleeding
AstraZeneca’s high hopes for cancer immunotherapy were dented on Thursday as the recruitment